<DOC>
	<DOCNO>NCT02505542</DOCNO>
	<brief_summary>Patients receive study drug one year ( Part A ) . If , initial run-in phase , sustain remission reach randomly split one three dose group another year ( Part B ) . The maintenance sustain remission analyze .</brief_summary>
	<brief_title>Study Evaluate Maintenance Sustained Remission axSpA With CZP Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Documented diagnosis adultonset axial SpondyloArthritis ( axSpA ) least 3 month ' symptom duration define specified Assessment SpondyloArthritis International Society ( ASAS ) criteria symptom duration le 5 year prior participation study Active disease Screening define Ankylosing Spondylitis Disease Activity Score ( ASDAS ) ≥ 2.1 Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) score ≥ 4 Spinal pain &gt; 4 0 10 Numerical Rating Scale ( NRS ) ( BASDAI Item 2 ) modify New York ( mNY ) negative subject : Creactive Protein ( CRP ) &gt; upper limit normal ( ULN ) and/or current evidence sacroiliitis Screening Magnetic Resonance Imaging ( MRI ) Inadequate response , contraindication , intolerant least 2 Nonsteroidal AntiInflammatory Drugs ( NSAIDs ) Presence total Spinal Ankylosis ( 'bamboo spine ' ) Diagnosis Inflammatory Arthritis Prior treatment experimental biological agent treatment Axial SpondyloArthritis ( SpA ) Exposure 1 TNFantagonist primary failure TNF antagonist therapy History current chronic recurrent infection High risk infection Recent live vaccination Concurrent malignancy history malignancy Class III IV congestive heart failure New York Heart Association ( NYHA ) Demyelinating disease central nervous system Female subject breastfeeding , pregnant plan become pregnant study within 3 month follow last dose investigational product Subjects condition , investigator 's judgment , would make subject unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Axial Spondyloarthritis</keyword>
	<keyword>axSpA</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Anti TNF-alpha</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Remission</keyword>
	<keyword>Spondylarthropathies</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Spinal Diseases</keyword>
	<keyword>Immunosuppressive Agents</keyword>
</DOC>